Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.77 |
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | PIKFYVE | Q9Y2I7 | 5/20 | 0.62 |
| ▸ | FES | P07332 | 1/20 | 0.62 |
| ▸ | FER | P16591 | 1/20 | 0.62 |
| ▸ | TYK2 | P29597 | 1/20 | 0.62 |
| ▸ | FRK | P42685 | 1/20 | 0.62 |
| ▸ | SYK | P43405 | 1/20 | 0.62 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.62 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429036 | 1.00 | MAPT (0.77) | MAPTKDM4ELMNAHPGDPIKFYVE | |
| SCHEMBL4402269 | 0.96 | KDM4E (0.72) | MAPTKDM4ELMNAHPGDPIKFYVE | |
| SCHEMBL425890 | 0.96 | KDM4E (0.72) | MAPTKDM4ELMNAHPGDPIKFYVE | |
| SCHEMBL430811 | 0.94 | KDM4E (0.69) | MAPTKDM4ELMNAHPGDPIKFYVE | |
| SCHEMBL430810 | 0.94 | KDM4E (0.69) | MAPTKDM4ELMNAHPGDPIKFYVE | |
| SCHEMBL18330253 | 0.87 | MAPT (1.00) | MAPTKDM4ELMNAHPGDPIKFYVE | |
| SCHEMBL428596 | 0.84 | MAPT (0.61) | MAPTKDM4ELMNAHPGDPIKFYVE | |
| SCHEMBL428597 | 0.84 | MAPT (0.61) | MAPTKDM4ELMNAHPGDPIKFYVE | |
| SCHEMBL429983 | 0.84 | MAPT (0.61) | MAPTKDM4ELMNAHPGDPIKFYVE | |
| SCHEMBL429984 | 0.84 | MAPT (0.61) | MAPTKDM4ELMNAHPGDPIKFYVE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687004-A4 | PYRIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2009-04-08 | — | — | EP | claimed |
| JP-2007510747-A | — | — | 2007-04-26 | — | — | JP | claimed |
| EP-1687004-A2 | PYRIDINE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | claimed |
| US-20050250774-A1 | Pyridine compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | claimed |
| WO-2005046603-A2 | PYRIDINE COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8173651-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173651-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173651-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-05-08 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20080167300-A1 | PYRIDINE COMPOUNDS | MADRIGAL PHARMACEUTICALS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080167300-A1 | PYRIDINE COMPOUNDS | MADRIGAL PHARMACEUTICALS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080167300-A1 | PYRIDINE COMPOUNDS | MADRIGAL PHARMACEUTICALS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-7338951-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338951-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167300-A1 | PYRIDINE COMPOUNDS | IL2, IL4, IL6 | MAPT 1165/4885KDM4E 2452/4885LMNA 2870/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | MAPT 4316/4885KDM4E 1015/4885LMNA 3579/4885 |
| US-20050250774-A1 | Pyridine compounds | IL2, IL4, IL6 | MAPT 1165/4885KDM4E 2452/4885LMNA 2870/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | MAPT 4316/4885KDM4E 1015/4885LMNA 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.